Brief: Zynerba Pharmaceuticals Presents Longer Term Tolerability And Efficacy Data Of Zygel In Children And Adolescents With Autism Spectrum Disorder At Society For Study Of Behavioural Phenotypes Conference 2021
09/09/2021 12:39
Sept 9 (Reuters) - Zynerba Pharmaceuticals Inc ZYNE.O :
* ZYNERBA PHARMACEUTICALS PRESENTS LONGER TERM TOLERABILITY
AND
EFFICACY DATA OF ZYGEL™ IN CHILDREN AND ADOLESCENTS WITH AUTISM
SPECTRUM DISORDER (ASD) AT THE SOCIETY FOR THE STUDY OF
BEHAVIOURAL PHENOTYPES (SSBP) CONFERENCE 2021
Source text for Eikon: ID:nGNX3XWMBh
Further company coverage: ZYNE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Zynerba Pharmaceuticals
See all newsBrief: Harmony Biosciences Completes Acquisition Of Zynerba Pharmaceuticals
Brief: Harmony Biosciences Announces Extension Of Tender Offer To Acquire Zynerba Pharmaceuticals, Inc.
Brief: Zynerba Pharmaceuticals Presents Positive Data From Phase 2 Inspire Trial
U.S. RESEARCH ROUNDUP-Easterly Government Properties, Visa, Zynerba Pharmaceuticals
Zynerba Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary